Key people Mark Ferguson (CEO) Founded October 2000 | Defunct May 2011 Number of employees approx 110 Ceased operations May 2011 | |
 | ||
Headquarters | ||
Renovo Group plc (formerly LSE: RNVO) was a biopharmaceutical company, which was founded in 1998 and was headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate Juvista, all 100 of Renovo's staff were laid off in 2011.
Contents
Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.
Products
Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.
Disambiguation
Renovo Group, PLC. has no affiliation with Renovo Neural, Inc. (www.renovoneural.com), a preclinical research organization founded in Cleveland, OH, USA, in 2008. Renovo Neural's business is focused on identifying and developing neural therapies for neurodegenerative diseases, including multiple sclerosis and Parkinson's Disease.